Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle

@article{Abdulla2020GlucagonlikeP1,
  title={Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle},
  author={H. Abdulla and B. Phillips and D. Wilkinson and M. Limb and T. Jandova and J. J. Bass and D. Rankin and J. Cegielski and Mariwan Sayda and H. Crossland and John P. Williams and Kenneth Smith and I. Idris and P. Atherton},
  journal={Aging Cell},
  year={2020},
  volume={19}
}
Despite its known insulin‐independent effects, glucagon‐like peptide‐1 (GLP‐1) role in muscle protein turnover has not been explored under fed‐state conditions or in the context of older age, when declines in insulin sensitivity and protein anabolism, as well as losses of muscle mass and function, occur. 

References

SHOWING 1-10 OF 51 REFERENCES
Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes
Blunting of insulin inhibition of proteolysis in legs of older subjects may contribute to age-related sarcopenia.
GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.
Characteristic of GLP-1 effects on glucose metabolism in human skeletal muscle from obese patients
Carbohydrate co-ingestion with protein does not further augment post-prandial muscle protein accretion in older men
...
1
2
3
4
5
...